Galmed Pharmaceuticals Ltd

NASDAQ:GLMD   12:14:00 PM EDT
2.39
+0.04 (+1.49%)
Products, Regulatory

Galmed Announces Approval Of Ind Application In China For Aramchol For The Treatment Of Nash & Fibrosis In The Global Phase 3 Armor Registrational Study

Published: 05/03/2021 12:45 GMT
Galmed Pharmaceuticals Ltd (GLMD) - Galmed Announces Approval of Ind Application in China for Aramchol for the Treatment of Nash & Fibrosis in the Global Phase 3 Armor Registrational Study.
Galmed Pharmaceuticals Ltd - China to Join Galmed's Phase 3 Armor Registrational Study for Treatment of Nash & Fibrosis.
Galmed Pharmaceuticals - Look Forward to Rapidly Initiating Enrollment in China Later in H2 2021.